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Abstract
OBJECTIVE: To compare the long-term effective-
ness of compound Ruanjianhugan(RJH)tablets and
interventional therapy (IT) in patients after resec-
tion of small hepatocellular carcinoma (HCC).
METHODS: A retrospective study was conducted
in 399 patients after resection of small HCC who
were admitted between January 1987 and Decem-
ber 2008 in the Department of Hepatobiliary Sur-
gery and Center of Minimlly Invasive Surgery,First
Affiliated Hospital of Guangxi Medical University.
Four groups were based on different therapy
modes: a TCM-only (TCMO) group, a TCM com-
bined with interventional therapy (TCM-IT) group,
an interventional therapy-only (ITO) group, and a
simple operation (SO) group. Prognostic factors
were correlated with overall survival (OS) and OS
rates were calculated with the Kaplan-Meier meth-
od, and multivariate analyses for factors affecting
survival were evaluated by the Cox proportional
hazard model.
RESULTS: The median OS was 151.20 months in
the TCM-IT group, 43.87 months in the ITO group,
and 20.77 months in the SO group. All survival
rates of the TCMO group were higher than those of
the other three groups (>50% ). The 5-, 10-, and
15-year OS in the TCMO and ITO patients were
83.94%, 45.50%, and 71.22% and 33.34%, 55.58%,
and 9.26%, respectively (risk ratio, 0.209; 95% confi-
dence interval, 0.126-0.347; P=0.000). Multivariate
analysis revealed that the independent risk factors
were therapy mode (P=0.000), sex (P=0.005), family
history (P=0.011), TNM Classification of Malignant
Tumor staging (P=0.000), medical care-seeking be-
havior (P=0.021), and maximum diameter (P=0.030).
CONCLUSION: Long-term oral use of compound
RJH tablets may improve OS for small HCC after re-
section compared with IT.
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INTRODUCTION
Liver cancer is the sixth most common cancer world-
wide with 626,000 new cases per year[1], half of which
are in China[2]. For small (tumors ≤5 cm in diameter)
hepatocellular carcinoma (HCC), early resection is gen-
erally accepted as the best way to prolong the survival
time[3,4], but postsurgical recurrence is the barrier to sur-
vival prolongation. The 5-year recurrence rate of HCC
after curative resection is >60% [5,6], and the 5-year re-
currence rate of small HCC after curative resection
may be as high as 43.5%[7]. Randomized controlled tri-
als on therapies including transcatheter arterial emboli-
zation (TAE) and transcatheter arterial infusion chemo-
therapy (TAI) confirming the effectiveness in prolong-
ing overall survival (OS) time are rare, so preventing re-
currence and metastasis of liver cancer has become a
current focal point[7,8]. Our prior study disclosed that
the combined use of TACE and traditional Chinese
medicine (TCM) were more advantageous in prolong-
ing duration of survival[9,10]. Guangxi is a high-risk re-
gion for HCC in China[11], and primary hepatic carci-
noma has ranked second in cancer mortality in
China[12]. This study in the First Affiliated Hospital of
Guangxi Medical University was designed to prove that
long-term oral Ruanjianhugan (RJH) tablets, a Chi-
nese herbal medicine compound, is more advantageous
in improving the OS for small HCC after resection
compared with interventional therapy (IT).This study
was approved by the appropriate ethics committees
and was performed in accordance with the ethical stan-
dards laid down in the Declaration of Helsinki. All per-
sons signed their informed consent prior to their inclu-
sion in the study.
METHODS
Subjects
A total of 1420 consecutive patients with HCC who
underwent curative resection from January 1987 to De-
cember 2008 were enrolled in this study by identifying
the diagnosis codes for HCC in the International Clas-
sification of Diseases, 10th Revision, Clinical Modifica-
tion (ICD-10) using the medical records of the First
Affiliated Hospital of Guangxi Medical University,
Nanning, China.
Inclusion and exclusion
Of the 1420 patients, 493 who were diagnosed with
HCC by postoperative histopathology and who had
small HCC (diameter≤5cm) met the inclusion criteri-
on. Of these 493 patients with small HCC, 94 were ex-
cluded for the following reasons: 21 underwent noncu-
rative resections, 4 died during hospitalization, 49 had
incomplete follow-up data, 14 underwent percutane-
ous ethanol injection therapy, and 6 underwent local
ablation therapy. The remaining 399 patients (346
male and 53 female) were included and retrospectively
analyzed.
This study was reviewed and approved by the Institu-
tional Research Committees of both Guangxi Medical
University (Nanning, China) and the Second Military
Medical University (Shanghai, China) according to
guidelines published by the Chinese Ministry of
Health, Labor and Welfare[13]. All patients signed in-
formed consent prior to their inclusion in the study,
and all records were kept confidential. Every patient in
this study agreed to long-term supervision by the doc-
tors from the Department of Hepatobiliary Surgery,
the First Affiliated Hospital of Guangxi Medical Uni-
versity (Nanning, China), and their names will not be
released at any time.
Trial design
These 399 patients were divided into four groups ac-
cording to the therapy mode: TCM-only (TCMO)
group (n=122), TCM combined with IT (TCM-IT)
group (n=68), IT-only (ITO) group (n=172), and sim-
ple operation (SO) group (n=37). The four groups
were comparable in age, sex, family history, medical
care-seeking behavior, hepatitis virus infection status,
cirrhosis status, Child-Pugh score, TNM staging, tu-
mor size and number, vascular invasion, tumor cap-
sule, and presence of portal vein invasion (Table 1).
TCMO group: Patients in the TCMO group took
long-term oral administration of compound RJH tab-
lets for 1 to 3 months after curative resection. Pro-
duced by Pharmaceutical Factory of Guangxi Medical
University, Nanning, China (production license No.
Gui ZzY 19950717), the RJH tablets comprised 10
medicinal materials: Ku Shen (Radix Sophorae Tonki-
nesis), Xia Ku Cao (Spica Prunellae), Hu Zhang (Rhi-
zoma Polygoni Cuspidati), Wu Wei Zi (Fructus
Schisandrae), Chi Shao (Radix Paeoniae Rubra), Nü
Zhen Zi (Fructus Ligustri Lucidi), San Qi (Radix No-
toginseng), Dan Shen (Salvia miltiorrhiza Bunge),
Huang Qi (Radix Astragali), and Sha Ren (Fructus
Amomi). Each tablet contained 0.31 g of medicines
equivalent to 6.0216 g of crude drug. The average dai-
ly dose was three tablets three times daily. A course of
treatment lasted 3 months, and patients received two
to three courses every year.
ITO group: These patients underwent postoperative in-
tervention treatment. A superselective catheter was in-
serted into the arteria hepatica propria or left/right he-
patic artery for TAI or TAE. Two to three drugs were
selected from epirubicin, hydroxycamptothecin, mito-
mycin, and fluorouracil for TAI, while medical adhe-
sives, spongia gelatinosa, Lipiodol, and Lipiodol Ultra
Fluid were selectively used as embolization agents at
different times during the treatment.
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TCM-IT group: These patients took long-term oral
administration of RJH tablets for 1 to 3 months after
curative resection combined with IT. SO group: The
SO group received no treatment after resection.
Table 1 Patient characteristics
Characteristic
Age (years)†
No. of lesion(s)†
Tumor diameter (cm)†
Male gender
Negative family history
Seeking behavior
Clinical symptoms
Healthy check-up
Negative HBs-Ag
Liver cirrhosis
No vascular invasion
Tumor capsule
Incomplete
Complete
Absent
No portal vein invasion
Tumor location
Left lobe
Right lobe
Caudate lobe
Child-Pugh classification
A
B
C
TNM stage
I
II
IIIa
IIIb
IIIc
IV
TCMO
(n=122)
45.82±11.28
1.04±0.20
3.44±1.16
108(88.52%)
116(95.08%)
81(66.39%)
41(33.61%)
52(42.62%)
75(61.48%)
109(89.34%)
23(18.85%)
95(77.87%)
4(3.28%)
116(95.08%)
40(32.79%)
80(65.57%)
2(1.64%)
109(89.34%)
12(9.84%)
1(0.82%)
103(84.43%)
13(10.66%)
6(4.92%)
—
—
—
ITO
(n=172)
48.32±10.09
1.09±0.28
3.53±1.01
150(87.21%)
160(93.02%)
104(60.47%)
68(39.53%)
50(29.07%)
118(68.60%)
133(77.33%)
50(29.07%)
113(65.70%)
9(5.23%)
160(93.02%)
35(20.35%)
136(79.07%)
1(0.58%)
147(85.47%)
22(12.79%)
3(1.74%)
128(74.42%)
28(16.28%)
11(6.40%)
1(0.58%)
2(1.16%)
2(1.16%)
TCM-IT
(n=68)
46.22±9.40
1.07±0.31
3.44±1.11
58(85.29%)
65(95.59%)
45(66.18%)
23(33.82%)
27(39.71%)
39(57.35%)
56(82.35%)
22(32.35%)
45(66.18%)
1(1.47%)
64(94.12%)
21(30.88%)
47(69.12%)
63(92.65%)
4(5.88%)
1(1.47%)
53(77.94%)
10(14.71%)
3(4.41%)
1(1.47%)
1(1.47%)
—
SO
(n=37)
45.95±11.21
1.19±0.46
3.57±1.01
30(81.08%)
33(89.19%)
26(70.27%)
11(29.73%)
16(43.24%)
22(59.46%)
30(81.08%)
13(35.14%)
24(64.86%)
.
35(94.59%)
9(24.32%)
26(70.27%)
2(5.41%)
31(83.78%)
4(10.81%)
2(5.41%)
25(67.57%)
8(21.62%)
2(5.41%)
1(2.70%)
.—
1(2.70%)
P
0.173
0.080
0.915
0.626
0.517
0.588
0.064
0.307
0.060
0.114
0.945
0.036*
0.411
0.543
Notes: *P<0.05, †Mean ± standard deviation TCM, traditional Chinese medicine; HBs-Ag, hepatitis B virus surface antigen; AFP,
a-fetoprotein; TNM, tumor, node, metastasis system; ECOG, Eastern Cooperative Oncology Group; ALT, glutamic-pyruvic transaminase;
AST, glutamic-oxaloacetic transaminase; TCMO, TCM-only group; TCM-IT, TCM combined with IT group; ITO, IT-only group; SO,
simple operation group.
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Assessment and follow-up
Outpatient and inpatient care was performed once ev-
ery 2 months during the first year, every 3 months dur-
ing the 2nd through 4th years, and semiannually after
5 years. Serum a-fetoprotein (AFP) levels, liver and kid-
ney function, B-ultrasonography, and X-ray examina-
tion (semiannual) were measured. If a suspected focus
of infection was discovered, CT or MRI sometimes al-
lowed prompt diagnosis prior to culture results; the di-
agnoses were confirmed by pathologic examination
with biopsy or digital signature algorithm if necessary.
A scholar, Professor Liang Shui-ting, was accredited as
the full-time professional medical staff member of the
second-level prevention group for HCC. Professor
Shui-ting followed up and recorded all patients' impor-
tant information, including treatment methods, ad-
verse reactions, recurrence, time of death, etc., every 3
months. Some patients were followed up by telephone
and correspondence as a matter of convenience. In ad-
dition, some information was obtained from the De-
partment of Medical Records of the hospital or local
clinics. The follow-up continued until the patients
died. The last follow-up was on February 28, 2009.
Primary endpoint. OS was defined as the time that
elapsed from surgery to death or the last follow-up.
The survival time of patients lost to follow-up was de-
fined as the last precise follow-up time, and the surviv-
al time of the patients still remaining until the end of
the study was statistical analyzed as the censored value.
Statistical analysis
Different groups of measurement data after normal dis-
tribution and homogeneity test of variances results
were compared using analysis of variance when varianc-
es were equal and nonparametric tests when variances
were not equal. Ranked data were analyzed using Co-
chran-Mantel-Haenszel tests. The analyses of survival
were performed by the Kaplan-Meier method, and the
survival was compared using the log-rank test. A multi-
variate regression analysis was performed using the Cox
proportional hazards model, and each group was as-
signed in the form of dummy variable for its different
therapy. Stepwise regression analysis was used for the
multivariate adjustment of all 15 clinicopathologic fac-
tors: age, sex, family history, medical care-seeking be-
havior, status of hepatitis virus infection, cirrhosis sta-
tus, Child-Pugh score, TNM staging, tumor location,
tumor size and number, vascular invasion, tumor cap-
sule, presence of portal vein invasion, and therapy mod-
el. For all analyses, P values were two-sided, and only
P<0.05 was considered statistically significant. Process-
ing and analysis of data were performed with the SPSS
10.0 statistical package (SPSS Inc., Chicago, IL, USA)
and SAS 9.1.3 statistical package (SAS Institute, Inc.,
Cary, NC, USA) and EPIDATA Version 3.1 (EpiData
Association, Odense, Denmark).
RESULTS
Comparison of clinicopathologic and pathological
features
Table 1 shows the comparison of 14 clinicopathologic
and pathological features. Only tumor location was
considered significant (P=0.036). The other factors did
not significantly differ among groups (P>0.05); tumor
location was proven to be a prognostic factor using uni-
variate analysis (Table 2).
Comparison of OS after surgery
TCMO group vs ITO group. The 5-, 10-, and 15-year
OS rates in the TCMO group (n=122) and ITO group
(n=172) were 83.94% and 45.50% , 71.22% and
33.34% , and 55.58% and 9.26% , respectively (P=
0.000; relative risk=0.209; 95% CI, 0.126-0.347) (Ta-
bles 2-4).
TCMO group vs TCM-IT group. The 5- and 10-year
OS rates in the TCMO group were 83.94% and
74.16%, respectively, and those in the TCM-IT group
were 71.22% and 57.10%, respectively (log-rank test,χ2 = 2.365; P=0.124) (Tables 2 and 3). There was no
significant difference between the two groups.
TCM-IT group vs ITO group. There was a trend to-
ward better OS rates in TCM-IT patients (5- and
10-year rates of 74.16% and 57.10% , respectively)
compared with ITO patients (5- and 10-year rates of
45.50% and 33.34%, respectively), and the difference
was significant (P<0.0001) (Tables 2 and 3).
TCMO group vs SO group. There was a trend toward
better OS rates in TCMO patients (5- and 10-year
rates of 83.94% and 71.22% , respectively) compared
with SO patients (5- and 10-year rates of 13.84% and
13.84% , respectively), and the difference was signifi-
cant (log-rank test, χ2 =74.407; P=0.000) (Tables 2
and 3).
ITO group vs SO group. The 5- and 10-year OS rates
in ITO patients were 45.50% and 13.84%, respective-
ly, and those in SO patients were 33.34% and 13.84%,
respectively (log-rank test, χ2 = 15.832, P=0.000) (Ta-
bles 2 and 3); there was a significant difference be-
tween the two groups.
Univariate and multivariate analysis for prognostic
factors
OS. Univariate analysis for OS was performed for pa-
tients (Table 2), and 7 of 15 variances were significant
prognostic factors (P<0.05): family history, tumor
number, vascular invasion, tumor location, Child-Pugh
classification, TNM staging, and therapy mode.
Multivariate survival analysis for OS was performed by
including all 15 prognostic factors to determine the in-
dependent prognostic factors. As shown in Table 4, the
six independent factors were as follows: therapy mode,
sex, family history, TNM staging, medical care-seeking
behavior, and tumor size.
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Results of the multivariate survival analysis also showed
that group (3), tumor size, TNM staging, and family
history were major risk factors of recurrence for small
HCC tumors (P<0.05; regression coefficient>0; rela-
tive risk 2.600, 1.208,1.366, 2.109,) (Table 4), while
medical care-seeking behavior, sex, the group 1) and
group 2) using different therapy modes were protective
factors (P<0.05; regression coefficient <0; relative risk
0.650, 0.431, 0.209, 0.293).
Table 2 Univariate analysis of prognostic risk factors associated with survival
Variables
Sex
Male
Female
Age
<60
≥60
Family history
Negative
Positive
Medical-care
seeking behavior
Clinical
symptoms
Healthy
check-up
Viral Hepatitis B
Negative
Positive
Tumor number
1
2
Maximum tumor diameter
< 2cm
2–3cm
3–5cm
Tumorcapsule
incomplete
complete
non-enveloped
Vascular invasion
Absent
Present
Liver cirrhosis
Negative
Positive
Portal vein
invasion
Negative
Positive
Tumor location
Left lobe
Right lobe
Caudal lobe
Child-Pugh
A
B
C
TNM staging
I
II
IIIa–IV
Therapy mode
TCMO
ITO
TCM -IT
SO
Patient
(n)
346
53
352
47
374
25
256
143
145
254
369
30
56
113
230
108
277
14
328
71
145
254
375
24
105
289
5
350
42
7
309
59
31
122
172
68
37
Median survi-
val(months)
104.43
123.63
120.33
45.27
120.33
31.17
104.43
123.63
105.17
119.37
120.33
34.23
171.30
105.17
104.43
59.23
140.20
—
123.63
38.37
120.33
104.43
105.17
119.37
145.93
98.30
12.77
119.37
105.17
20.80
140.20
38.37
56.83
—
43.87
151.20
20.77
Kaplan–Meier survival rate (%)
1-year
91.08
89.85
90.71
92.21
92.34
78.41
88.77
94.76
89.25
91.90
90.41
88.7
96.00
93.80
89.57
87.60
92.07
91.67
92.19
85.17
89.30
91.90
91.49
81.73
90.21
91.39
80.00
91.28
91.67
71.43
93.05
87.71
76.00
94.76
91.85
98.53
63.92
2-year
80.35
84.69
81.71
75.40
81.56
69.70
76.55
88.58
80.44
81.15
81.31
65.4
96.00
85.14
78.11
79.66
81.25
81.48
83.64
68.26
77.64
82.81
81.07
76.93
82.39
81.01
40.00
81.91
76.69
35.71
85.51
67.09
64.53
91.69
74.42
93.38
48.20
3-year
69.35
81.30
71.94
62.61
72.36
48.25
68.01
75.54
69.49
71.47
71.13
45.6
90.67
71.23
68.39
64.63
73.51
61.11
74.46
54.35
70.75
71.07
70.60
71.43
75.59
69.34
40.00
71.82
63.91
35.71
75.99
53.77
56.18
89.27
55.74
87.54
34.60
5year
59.02
67.39
61.64
48.70
61.34
42.22
56.97
65.44
58.56
60.82
60.35
23.1
73.52
63.12
57.64
49.64
63.64
61.11
64.26
39.38
65.30
57.74
59.64
64.94
69.49
56.99
20.00
60.87
63.91
—
68.28
31.16
45.78
83.94
45.50
74.16
13.84
10-year
45.97
63.43
50.57
25.97
50.81
—
43.63
55.76
47.62
48.08
48.28
17.5
65.35
47.60
46.29
30.94
53.24
61.11
52.45
27.01
52.02
46.13
48.74
41.75
58.11
44.62
20.00
49.79
25.56
—
55.79
24.93
30.04
71.22
33.34
57.10
13.84
15-year
29.80
47.57
33.01
25.97
33.45
—
31.24
33.13
39.68
27.67
32.80
15.5
—
35.70
32.11
20.63
36.42
61.11
34.13
20.25
35.73
29.27
32.87
20.87
29.05
34.64
20.00
32.57
25.56
—
36.88
16.62
15.02
55.58
9.26
—
13.84
P value
0.254
.
0.208
.
0.0049*
0.0966
.
0.8781
.
0.003*
0.2753
.
.
0.0501
.
.
0.0003*
0.7046
0.7752
0.0135*
0.0152*
.
.
<.0001*
.
<0.0001﹡
Notes: *P<0.05. Abbreviations are the same as those in Table 1.
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Figure 1 Comparison of overall survival curves using four dif-
ferent interventions. Log rank tests: A vs C, P=0.124; A vs B,
P=0.000; A vs D, P=0.000. A=TCM only, B=interventional
therapy alone, C=TCM+interventional therapy, D=simple op-
eration.
The results showed that the risk of death from HCC in
patients in the TCMO group was reduced to 0.209
than in ITO groups and in TCM-IT groups reduced to
0.293 in patients in the ITO groups, respectively, while
the risk of death in patients in the SO group was 2.600
times greater than that in patients in the ITO group.
Loss to follow-up. Of the 399 patients in the study, the
longest survival time was 22 years. Ninety-three of 399
patients lived for more than 5 years; 56 patients of 399
patients were eventually lost to follow-up. The overall
follow-up loss rate was 14.0% (56/399); the follow-up
loss rate in the TCMO and ITO groups was 13.1%
(16/122) and 15.7% (27/172) respectively.
Adverse reactions: No significant drug-related adverse
effects were observed in the patients who had taken
long-term oral administration of compound RJH. Very
few patients suffered from frequent nocturnal urina-
tion, but this symptom quickly disappeared after treat-
ment with oral Liuwei Dihuang pills.
Table 3 Pairwise comparisons
O S
Group
A vs B
A vs C
A vs D
B vs C
B vs D
C vs D
Chi-Square
2.365
37.092
74.407
14.498
46.142
15.832
Pa
0.124
0.000
0.000
0.000
0.000
0.000
Notes: aLog-rank test. A, TCMO; B, TCM-IT; C, ITO; D, SO.
Table 4 Multivariate analysis of independent prognostic risk factors by Cox model
OS
Family
Medical-care
Tumor
Variable
Group
Group 1
Group 2
Group 3
sex
history
TNM
Seeking behavior
size
Parameter Estimate
-1.564
-1.228
0.955
-0.843
0.746
0.312
-0.431
0.189
Standard Error
0.258
0.267
0.231
0.298
0.294
0.080
0.186
0.087
Chi-Square
83.717
36.681
21.181
17.164
7.990
6.422
15.133
5.366
4.694
P
0.000
0.000
0.000
0.000
0.005
0.011
0.000
0.021
0.030
Relative risk
0.209
0.293
2.600
0.431
2.109
1.366
0.650
1.208
95% CI
0.126-0.347
0.174-0.494
1.654-4.086
0.240-0.772
1.184-3.755
1.167-1.598
0.452-0.936
1.018-1.433
Notes: *P<0.05. Abbreviations are the same as those in TABLE 1. Group 1, TCMO vs ITO groups; Group 2, TCM-IT vs ITO groups;
Group 3, SO vs ITO groups . Ruanjianhugan in resected hepatocellular carcinoma.
DISCUSSION
So far, radical resection still is the primary treatment to
increase the total operative efficacy of small HCC tu-
mors[14,15]. IT has been clinically applied since the late
1980s. Medical professionals in China recently reached
a consensus in which experts agreed that hepatic arteri-
al infusion chemotherapy and hepatic arterial emboliza-
tionare the main IT methods and suggested IT for HC-
Caround 40 days after noncurative hepatectomy[16].
However, preliminary studies showed that IT before
surgery for large HCC tumors did not prolong dis-
ease-free survival[17]. In addition, there was still some de-
bate about the effectiveness of IT in preventing HCC
recurrence after curative resection for small tumors[18],
while there were fewer reports comparing TCM with
IT in China.
Over the past 20 years, TCM treatment of tumors has
attracted increasing attention. The molecular mecha-
nism of Chinese medicines in treatment of cancer was
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recently elucidated by scholars in China. This has
aroused great responses in international medical cir-
cles[19-21]. The present study found that the therapy
mode and family history were risk factors affecting OS,
while TCM as a beneficial intervention in preventing
HCC recurrence after curative resection for small tu-
mors was confirmed in this study; and this finding re-
garding family history coincides with the conclusion
about familial aggregation by scholars in China[22].
It is considered in TCM that the basic pathogeneses
leading to liver cancer are imbalances of integrity and
functional regulation of the whole body[23,24], and this
viewpoint coincides with the theory about cancer in
modern medicine; IT for tumors has attracted increas-
ing attention[25]. Based on long-term clinical practice in
treatment of cancer, scholars in China were in agree-
ment that the prognosis of malignant tumors depends
on the tumor's biological characteristics[26], and some
preclinical trials have demonstrated that RJH tablets
play a role in prevention in highly susceptible popula-
tions with important risk factors for HCC[27,28]. In the
present study, the 5- and 10-year survival rates in TC-
MO patients were markedly higher than those in re-
cent reports (the 5- and 10-year survival rates were
58.20% and 38.47% , respectively) [29]. Studies on
whether this effectiveness is associated with regulation
and control of invasion and metastasis of liver cancer
cells are still in the early stages, and these findings need
to be replicated by further clinical trials.
From the 1970s, the epidemiology of secondary preven-
tion strategies for hepatoma had undergone intensive
research in Nanning, Guangxi, and follow-up proce-
dures for liver cancer were set up in Department of
Hepatobiliary Surgery, First Affiliated Hospital of
Guangxi Medical University with detailed follow-up
data recorded over time. However, this study also has
some limitations. First, we could not sufficiently eluci-
date the molecular mechanism of RJH in improving
the clinical therapeutic effect for its intricate compo-
nents, and further studies are necessary to clarify it. Sec-
ond, as a single-center study, the sample size was not
large enough, this may have affected the reliability of
the results. Third, as a retrospective study, losses to fol-
low-up were inevitable. In this study, the overall fol-
low-up rate was 14.0% (56/399), and the follow-up
rate in the TCMO group was 13.1% (16/122). For pa-
tients who were lost to follow-up, we had to take their
last follow-up time as the data for analysis. These un-
controllable factors may have led to bias, and as a retro-
spective study, the reliability was restricted to a cer-
tain extent.
In conclusion, this study shows that long-term oral use
of compound RJH tablets after resection for small
HCC may improve OS compared with IT. Although
the exact effect and mechanism need to be explored by
further prospective clinical studies, this research pro-
vides a basis to verify the clear advantage of using
TCM for patients after resection for small HCC tu-
mors.
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